Journal of Blood Disorders & Transfusion

Uncommon Bone Marrow Findings in a Patient with Hemolytic Anemia

Allan Layton^* Department of Life and Health Sciences, Aston University, Birmingham, United Kingdom
^*Correspondence: Allan Layton, Department of Life and Health Sciences, Aston University, Birmingham, United Kingdom, Email:

Received: 29-Aug-2025, Manuscript No. JBDT-25-30353; Editor assigned: 01-Sep-2025, Pre QC No. JBDT-25-30353 (PQ); Reviewed: 15-Sep-2025, QC No. JBDT-25-30353; Revised: 22-Sep-2025, Manuscript No. JBDT-25-30353 (R); Published: 29-Sep-2025, DOI: 10.4172/2155-9864.25.S16.077

Description

Q fever is a zoonotic infection caused by Coxiella burnetii, an intracellular bacterium capable of inducing a wide range of clinical findings. While the disease often presents with fever, pneumonia, or hepatitis, it can extend to less anticipated areas, including the hematologic system. Hemolytic anemia is a rare but noteworthy manifestation, presenting diagnostic difficulties due to its overlap with autoimmune, infectious and marrowrelated disorders. Bone marrow involvement adds to the complexity of Q fever because the organism can persist within macrophages, influencing the regulation of blood cell production. When combined with extensive inflammation, this environment may contribute to the development of hemolytic anemia. This article discusses the biological mechanisms, diagnostic features and clinical implications of an atypical presentation involving marrow disruption and anemia.

Coxiella burnetii typically enters the body through inhalation of contaminated aerosols arising from livestock, particularly cattle, sheep and goats. The organism is highly resistant to environmental stress and quickly establishes itself within host macrophages. Once inside these cells, it adapts to acidic intracellular compartments, enabling long-term persistence. Acute Q fever often presents with high fever, headache, malaise and respiratory symptoms, whereas chronic Q fever is associated with endocarditis or vascular infections. The organism influences the host immune system by stimulating proinflammatory cytokines and altering macrophage function. This effect extends to hematologic processes because macrophages participate in iron recycling, erythrocyte turnover and regulation of erythropoiesis. When these pathways become disrupted, blood cell abnormalities may arise, including anemia.

Hemolytic anemia in Q fever, however, is extremely uncommon. Reported cases suggest involvement of immune-mediated destruction, macrophage activation, or cytokine-driven alterations in red cell survival. Unlike classical autoimmune hemolytic anemia, the destruction in Q fever may be multifactorial, influenced by both direct immune activity and the inflammatory environment produced by the infection. Bone marrow involvement has been reported in both acute and chronic Q fever, though it remains an unusual presentation. Marrow alterations may include granuloma formation, macrophage expansion, or changes in overall cellularity. The organism’s affinity for mononuclear phagocytes creates the potential for marrow infiltration when infection becomes systemic.

Within the marrow, activated macrophages may influence erythropoiesis by altering cytokine levels or disrupting normal hematopoietic niches. This may reduce the marrow’s compensatory response to peripheral hemolysis, prolonging anemia or altering its severity. Additionally, granulomatous lesions may reflect the immune system’s attempt to contain persistent infection but also interfere with marrow function. A shift in erythroid maturation or abnormalities in progenitor cell development may also appear, particularly when cytokine overproduction suppresses erythropoiesis. These changes can produce a mixed clinical picture in which the marrow attempts to compensate for hemolysis but is simultaneously impaired by infection-driven inflammation.

Several mechanisms may contribute to hemolytic anemia in this context. Immune dysregulation plays a significant role because Q fever stimulates extensive activation of the immune system. Autoantibodies can occasionally develop during acute infection, targeting red cells and resulting in premature destruction. Complement activation may further intensify hemolysis by damaging red cell membranes. Inflammatory cytokines released during infection can also impair red cell survival. Oxidative stress resulting from systemic inflammation weakens membrane stability, making erythrocytes more vulnerable to destruction. Finally, marrow involvement itself restricts the production of new red cells, slowing recovery and exacerbating anemia.

Conclusion

Bone marrow involvement in Q fever represents a rare but significant aspect of the disease. When paired with hemolytic anemia, it produces a challenging clinical scenario that requires a broad diagnostic perspective and careful interpretation of laboratory findings. Early recognition, supported by environmental history and targeted testing, can guide clinicians toward effective treatment. As documentation of atypical cases increases, the medical community gains a clearer understanding of how Q fever affects the hematologic system, improving patient outcomes and clinical decision-making.

References

1. Scheckel CJ, Go RS. Autoimmune Hemolytic Anemia: Diagnosis and Differential Diagnosis. Hematol Oncol Clin North Am. 2022;36(2):315-324.

   [Crossref][Google Scholar][PubMed]

2. Hosokawa K, Nakao S. Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria. Semin Hematol. 2022;59(3):143-149.

   [Crossref][Google Scholar][PubMed]

3. Yui JC, Brodsky RA. Updates in the management of warm autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2022;36(2):325-339.

   [Crossref][Google Scholar][PubMed]

4. Rangnekar A, Shenoy M S, Mahabala C, Balanthimogru P. Impact of baseline fluorescent antinuclear antibody positivity on the clinical outcome of patients with primary autoimmune hemolytic anemia. Hematol Transfus Cell Ther. 2023;45(2):204-210.

   [Crossref][Google Scholar][PubMed]

5. Luyten U, Peeraer S, Pirlet C, Khaouch Y, Streel C, Deneys V. O-negative blood shortage management in a university hospital: Impact of transfusing RhD-positive red blood cells to RhD-negative patients. Transfus Clin Biol. 2023;30(4):402-409.

   [Crossref][Google Scholar][PubMed]

6. Guarente J, Tormey C. Transfusion support of patients with myelodysplastic syndromes. Clin Lab Med. 2023;43(4):669-683.

   [Crossref][Google Scholar][PubMed]

7. Dass J, Nayak AR, Puri V, Aggarwal M. Congenital dyserythropoietic anemia in children: Case series with review of literature. Pediatr Hematol Oncol J. 2024;9(2):55-61.

   [Crossref][Google Scholar]

8. Kwong YL, Zhang H, Wang X, Tse E. Epidemiology of mature T-cell and NK-cell neoplasms: East and West. Lancet Reg Health West Pac. 2025;62.

   [Crossref][Google Scholar][PubMed]

9. Chouhan S, Ajazuddin, Jain P. Novel Pathway and Recent Advances for Targeting Sickle Cell Anemia through Novel Drug Delivery System. Cardiovasc Hematol Agents Med Chem. 2024.

   [Crossref][Google Scholar][PubMed]

10. Carubbi F, Alunno A, Matone E, Lucchesi A, Musuraca G, Ferri C. Intersecting paths between autoimmunity and bone marrow fibrosis: The case of autoimmune myelofibrosis. Autoimmun Rev. 2025:103893.

    [Crossref][Google Scholar][PubMed]